The United States Food and Drug Administration (U.S. FDA) has recently approved an ICI (Atezolizumab, an anti-PD-L1 antibody, manufactured by Genentech, San Francisco, CA, United States) in combination with first-line chemotherapy for SCLC treatment. Here, CD274 is linked to small cell lung carcinoma.